Xeris Biopharma Holdings (XERS) Net Margin (2020 - 2026)

Xeris Biopharma Holdings has reported Net Margin for 7 years, with the latest figure at 2.69% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin rose 1802.0% year-over-year to 2.69%; the trailing twelve-month figure through Mar 2026 stood at 3.81% (up 2407.0% YoY), and the FY2025 full-year result was 0.19%, up 2719.0% from the prior year.
• Net Margin for Q1 2026 stood at 2.69%, down from 12.91% in the prior quarter.
• The five-year high for Net Margin was 12.91% in Q4 2025, with the low at 152.74% in Q1 2022.
• Historically, Net Margin has averaged 37.88% across 5 years, with a median of 30.16% in 2023.
• Annual changes were most pronounced in 2022 — Net Margin surged 20548 bps — and 2024, when it sank 377 bps.
• Xeris Biopharma Holdings' Net Margin stood at 39.01% in 2022, then rose by 23 bps to 30.16% in 2023, then jumped by 72 bps to 8.51% in 2024, then jumped by 252 bps to 12.91% in 2025, then slumped by 79 bps to 2.69% in 2026.
• The last three Net Margin figures came in at 2.69% (Q1 2026), 12.91% (Q4 2025), and 0.83% (Q3 2025), per Business Quant data.